12,372 trials
Open-Angle Glaucoma · Ocular Hypertension
Primary: Mean IOP — 18.61; 19.84; 18.00; 19.37 mm Hg — p=<0.01
Breast Adenocarcinoma · DS Stage I Plasma Cell Myeloma · DS Stage II Plasma Cell Myeloma
Primary: Percentage of Participants With at Least One Skeletal-related Event (SRE) Within 2 Years After Randomization — 67.6; 67.9 percentage of participants — p=<=.05
Respiratory Syncytial Virus Infections
Primary: Part A: Serum Concentration of Suptavumab Over Time — 280; 177; 145; 128 mg/L
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
Primary: Median Progression Free Survival (PFS) (Months) — 18.9; 10.2; 17.8; 9.8 Months — p=<0.0001
Type 1 Diabetes Mellitus
Primary: Adjusted Mean Change From Baseline in HbA1c at Week 24 — -0.34; -0.39; 0.03 HbA1c (%) — p=<0.0001
Macular Edema · Uveitis
Primary: Proportion of Baseline Central Subfield Thickness Observed at 8 Weeks — .77; .61; .54 proportion of baseline retinal thickness — p=<0.0001
Opioid Use Disorder · Opioid-related Disorders
Primary: Participants With Treatment-Emergent Adverse Events (TEAE) During the Treatment Period — 71; 14; 5; 0 Participants
Rheumatoid Arthritis
Primary: Change From Baseline in Disease Activity Score Based on 28-joints Count and Erythrocyte Sedimentation Rate (DAS28-ESR) at Week 24 — 5.80; -3.07 units on a scale
Diabetes Mellitus, Type 1
Primary: Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26 for Full Analysis Set (FAS) (Observed Cases [OC]) — 0.20; -0.09; -0.25; -0.33 Percentage (%) — p=<0.0001
HIV-1 Infection
Primary: Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the US FDA-Defined Snapshot Algorithm — 1.7; 1.7 percentage of participants — p=1.00
Asthma
Primary: Number of Patients/Caregivers Who Successfully Administered Benralizumab 30 mg Subcutaneously (SC) by Injection With an AI Device at Home — 113; 112; 108 Participants
Fabry Disease
Primary: Annualized Rate Of Change From Baseline To Month 18 In Measured Glomerular Filtration Rate — -4.35; -3.24 mL/min/1.73 m^2/year
Papilloma Viral Infection
Primary: Geometric Mean Titers (GMTs) to HPV Types 6/11/16/18 — 758.3; 618.4; 681.7; 769.1 milli Merck U/mL — p=<0.001
Type 2 Diabetes Mellitus
Primary: Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24 — -0.37; -0.03 percent — p=<0.001
Arthritis, Rheumatoid; Arthritis, Psoriatic
Primary: Injection Site Pain — 23.6; 19.8 mm — p=0.048